Since March 2015, the nivolumab (anti-PD-1 monoclonal antibody) has been approved by the US Food and Drug Administration (FDA), as the second-line treatment for the patients with advanced NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.